Published by Coherent Market Insights
Posted on September 9, 2021
Global Disease Control and Prevention Vaccine Market, by Product Type (Live-attenuated, Inactivated, Recombinant Sub Unit, and Toxoid), by Type (Monovalent and Multivalent), by Route of Administration (Oral and Injectable), by Age Group (Pediatric Vaccine and Adult Vaccine), and by Indication (Infectious Disease, Cancer, and Other Indications) is estimated to be valued at US$ 41.12 billion in 2017 and is estimated to exhibit a CAGR of 12.1% over the forecast period (2021-2025).
Get Your Sample Copy of the Disease Control And Prevention Vaccine Market Report 2021
The increasing product launches by market players coupled with rising government immunization programs are the major factors that are expected to drive growth of the global disease control and prevention vaccine market over the forecast period. Moreover, vaccines aids in controlling and preventing viral and bacterial diseases. Vaccines for infectious disease plays an important role in reducing disease incidence and burden of vaccine preventable disease. For instance, according to the Centers for Disease Control and Prevention (CDC), 2013, around 226,000 people are hospitalized every year and around 3,000-49,000 people are reported to die due to influenza and its complications.
Moreover, global efforts are made to tackle infectious disease by better surveillance and immunization system. For instance, according to the World Health Organization (WHO), incidence of polio decreased by 99% in 2018 compared to 1988, which is attributed to global initiatives for polio eradication by public and private organizations. Furthermore, increasing government initiatives to strengthen immunization program are expected to further boost growth of the disease control and prevention vaccine market. For instance, in 2017, Minister of Health from 194 countries supported Global Vaccine Action Plan to prevent millions of death through more access to vaccine by 2020. Moreover, key players are focusing on developing new vaccines with low price offering better safety and immunity for the disease.
Browse 47 Market Data Tables and 45 Figures spread through 210 Pages and in-depth TOC on “Disease Control and Prevention Vaccine Market, by Product Type (Live-attenuated, Inactivated, Recombinant Sub Unit, and Toxoid), by Type (Monovalent and Multivalent), by Route of Administration (Oral and Injectable), by Age Group (Pediatric Vaccine and Adult Vaccine), and by Indication (Infectious Disease, Cancer, and Other Indications) – Global Forecast to 2025”.
Additionally, key players in vaccine market are focusing on research and development to develop new vaccines with low cost, offering better safety and immunity for the disease and to expand their product portfolio. For instance, in 2017, GlaxoSmithKline plc, received the U.S. FDA approval for phase III clinical trial of its product Shingrix, a recombinant sub unit vaccine for shingles infection in adults. Moreover, manufacturers are focusing on developing vaccines by targeting diseases such as HIV or dengue to expand their product portfolio. For instance, Sanofi received the U.S. FDA approval for its dengue vaccine, Dengvaxia, in 2018.
Key players are also focusing on adopting growth strategies such as mergers and acquisitions, in order to strengthen their market position. For instance, in 2014, Pfizer Inc., acquired Baxter’s portfolio including marketed vaccines valued at US$ 648 million. The portfolio includes NeisVac-C and FSME-IMMUN/TicoVac vaccines against meningitis.
Key takeaways of the Disease Control and Prevention Vaccine Market:
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/1500
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Disease Control and Prevention Vaccine Market Share Expected to Gain US$ 102.54 Billion, at a 12.1% CAGR by 2025 | Industry Size, Latest Updates, Growth Opportunities and Regional Scope from 2021 appeared first on Gatorledger.
Global Disease Control and Prevention Vaccine Market, by Product Type (Live-attenuated, Inactivated, Recombinant Sub Unit, and Toxoid), by Type (Monovalent and Multivalent), by Route of Administration (Oral and Injectable), by Age Group (Pediatric Vaccine and Adult Vaccine), and by Indication (Infectious Disease, Cancer, and Other Indications) is estimated to be valued at US$ 41.12 billion in 2017 and is estimated to exhibit a CAGR of 12.1% over the forecast period (2021-2025).
Get Your Sample Copy of the Disease Control And Prevention Vaccine Market Report 2021
The increasing product launches by market players coupled with rising government immunization programs are the major factors that are expected to drive growth of the global disease control and prevention vaccine market over the forecast period. Moreover, vaccines aids in controlling and preventing viral and bacterial diseases. Vaccines for infectious disease plays an important role in reducing disease incidence and burden of vaccine preventable disease. For instance, according to the Centers for Disease Control and Prevention (CDC), 2013, around 226,000 people are hospitalized every year and around 3,000-49,000 people are reported to die due to influenza and its complications.
Moreover, global efforts are made to tackle infectious disease by better surveillance and immunization system. For instance, according to the World Health Organization (WHO), incidence of polio decreased by 99% in 2018 compared to 1988, which is attributed to global initiatives for polio eradication by public and private organizations. Furthermore, increasing government initiatives to strengthen immunization program are expected to further boost growth of the disease control and prevention vaccine market. For instance, in 2017, Minister of Health from 194 countries supported Global Vaccine Action Plan to prevent millions of death through more access to vaccine by 2020. Moreover, key players are focusing on developing new vaccines with low price offering better safety and immunity for the disease.
Browse 47 Market Data Tables and 45 Figures spread through 210 Pages and in-depth TOC on “Disease Control and Prevention Vaccine Market, by Product Type (Live-attenuated, Inactivated, Recombinant Sub Unit, and Toxoid), by Type (Monovalent and Multivalent), by Route of Administration (Oral and Injectable), by Age Group (Pediatric Vaccine and Adult Vaccine), and by Indication (Infectious Disease, Cancer, and Other Indications) – Global Forecast to 2025”.
Additionally, key players in vaccine market are focusing on research and development to develop new vaccines with low cost, offering better safety and immunity for the disease and to expand their product portfolio. For instance, in 2017, GlaxoSmithKline plc, received the U.S. FDA approval for phase III clinical trial of its product Shingrix, a recombinant sub unit vaccine for shingles infection in adults. Moreover, manufacturers are focusing on developing vaccines by targeting diseases such as HIV or dengue to expand their product portfolio. For instance, Sanofi received the U.S. FDA approval for its dengue vaccine, Dengvaxia, in 2018.
Key players are also focusing on adopting growth strategies such as mergers and acquisitions, in order to strengthen their market position. For instance, in 2014, Pfizer Inc., acquired Baxter’s portfolio including marketed vaccines valued at US$ 648 million. The portfolio includes NeisVac-C and FSME-IMMUN/TicoVac vaccines against meningitis.
Key takeaways of the Disease Control and Prevention Vaccine Market:
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/1500
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Disease Control and Prevention Vaccine Market Share Expected to Gain US$ 102.54 Billion, at a 12.1% CAGR by 2025 | Industry Size, Latest Updates, Growth Opportunities and Regional Scope from 2021 appeared first on Gatorledger.
